Literature DB >> 3030907

[Effects of KT1-32 on acute gastric lesions and duodenal ulcers induced in rats].

S Okabe, K Takeuchi, Y Mori, O Furukawa, Y Yamada.   

Abstract

We studied the effects of KT1-32 (sodium guaiazulene 3-sulfonate) on development of various acute gastric lesions and duodenal ulcers induced in rats. Male Donryu or Sprague-Dawley rats (220-270 g), fasted (but allowed free access to water) for 24 or 48 hr before the experiments, were used. KT1-32 (dissolved in distilled water, 10-100 mg/kg), given p.o. or intraduodenally (i.d.), dose-dependently inhibited the development of gastric lesions induced by HCl X ethanol (60% ethanol in 150 mM HCl), HCl X aspirin (aspirin 100 mg/kg in 150 mM HCl) or aspirin (150 mg/kg in pylorus-ligated preparation) and Shay ulcers (14 hr pylorus ligation). KT1-32 (30 and 100 mg/kg), given p.o. twice (9.5 hr apart), significantly inhibited the development of duodenal ulcers induced by mepirizole (200 mg/kg, s.c.), but did not inhibit gastric lesions developed simultaneously. KT1-32 (30 and 100 mg/kg), given p.o. or i.d., significantly reduced gastric acid secretion when examined using pylorus ligation preparations. KT1-32 (100 mg/kg, i.d.) had no effect on basal and suppressed duodenal HCO3- secretion by mepirizole. These results suggest that KT1-32 is a promising drug for the treatment of gastritis and peptic ulcers.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3030907     DOI: 10.1254/fpj.88.467

Source DB:  PubMed          Journal:  Nihon Yakurigaku Zasshi        ISSN: 0015-5691


  2 in total

1.  Therapeutic effect of egualen sodium (KT1-32), a new antiulcer agent, on chronic gastritis induced by sodium taurocholate in rats.

Authors:  S Mochizuki; M Matsumoto; S Wakabayashi; K Kosakai; A Tomiyama; S Kishimoto
Journal:  J Gastroenterol       Date:  1996-12       Impact factor: 7.527

2.  Management of afatinib-induced stomatitis.

Authors:  Saeko Kato; Anna Saito; Naomi Matsuda; Hisako Suzuki; Midori Ujiie; Shinya Sato; Kunihiko Miyazaki; Takahide Kodama; Hiroaki Satoh
Journal:  Mol Clin Oncol       Date:  2017-03-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.